추천 제품
제품명
Camptothecin, 10-Hydroxy-, Camptotheca acuminata, A cell-permeable powerful DNA topoisomerase I inhibitor.
Quality Level
분석
≥95% (HPLC)
양식
powder
제조업체/상표
Calbiochem®
저장 조건
OK to freeze
색상
pale yellow
solubility
DMSO: 5 mg/mL
배송 상태
ambient
저장 온도
2-8°C
SMILES string
[n]21c(cc5c([c]2=O)COC(=O)C5(O)CC)c3nc4c(cc3C1)cc(cc4)O
InChI
1S/C20H16N2O5/c1-2-20(26)14-7-16-17-11(5-10-6-12(23)3-4-15(10)21-17)8-22(16)18(24)13(14)9-27-19(20)25/h3-7,23,26H,2,8-9H2,1H3
InChI key
HAWSQZCWOQZXHI-UHFFFAOYSA-N
일반 설명
A cell-permeable powerful DNA topoisomerase I inhibitor. Reduces DNA synthesis in vitro in murine hepatoma cells. Has selective inhibitory effect on the phosphorylation of histone H1 and H3, but less effect on other histones.
A cell-permeable, powerful DNA topoisomerase I inhibitor. Reduces DNA synthesis in vitro in murine hepatoma cells. Inhibits the proliferation of hepatoma HepG2, Bcl-7402 and Bcl-7404 cells in a dose-dependent manner. Has selective inhibitory effect on the phosphorylation of histones H1 and H3, but is less effective on other histones.
생화학적/생리학적 작용
Cell permeable: yes
Primary Target
DNA topoisomerase I
DNA topoisomerase I
Product does not compete with ATP.
Reversible: no
경고
Toxicity: Irritant (B)
재구성
Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
기타 정보
Zhang, X.W., et al. 1999. Anticancer Drugs.10, 569.
Ling, Y.H., et al. 1993. Anticancer Res. 13, 1613.
Wani, M.C., and Wall, M.E. 1969. J. Org.Chem.34, 1364.
Ling, Y.H., et al. 1993. Anticancer Res. 13, 1613.
Wani, M.C., and Wall, M.E. 1969. J. Org.Chem.34, 1364.
법적 정보
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
신호어
Danger
유해 및 위험 성명서
Hazard Classifications
Acute Tox. 3 Oral - Muta. 1B
Storage Class Code
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
WGK
WGK 3
Flash Point (°F)
Not applicable
Flash Point (°C)
Not applicable
시험 성적서(COA)
제품의 로트/배치 번호를 입력하여 시험 성적서(COA)을 검색하십시오. 로트 및 배치 번호는 제품 라벨에 있는 ‘로트’ 또는 ‘배치’라는 용어 뒤에서 찾을 수 있습니다.
이미 열람한 고객
Nucleic acids research, 49(13), 7476-7491 (2021-07-02)
Poly (ADP-ribose) polymerase inhibitor (PARPi)-based therapies initially reduce tumor burden but eventually lead to acquired resistance in cancer patients with BRCA1 or BRCA2 mutation. To understand the potential PARPi resistance mechanisms, we performed whole-genome CRISPR screens to discover genetic alterations
자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..
고객지원팀으로 연락바랍니다.